Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study

Nanobiotix NBTX shares were up around 13% during the pre-market hours on Tuesday after the company announced that it has initiated dosing in a mid-stage study evaluating a potential first-in-class radioenhancer, JNJ-1900 (NBTXR3), to treat lung cancer patients. The candidate was added to Nanobiotix’s pipeline following a licensing deal for the global co-development and commercialization with pharma bigwig, Johnson & Johnson JNJ, in 2023.The company stated that it has dosed the first patient with JNJ-1900 in the phase II CONVERGE study to treat patients with Stage 3 unresectable non-small cell lung cancer (NSCLC). The eligibility criteria for this study include NSCLC patients receiving standard-of-care chemoradiation followed by consolidation immunotherapy with AstraZeneca’s Imfinzi (durvalumab). Per the global licensing agreement with Nanobiotix, Johnson & Johnson is responsible for funding the CONVERGE study.In the past three months, NBTX shares have plunged 40.2% compared with the industry’s 10.6% decline.Image Source: Zacks Investment ResearchNBTX’s Developmental Program for JNJ-1900 in CancerNanobiotix’s pipeline comprises only JNJ-1900, which is being evaluated across multiple solid tumor indications as a single agent or in combination with anti-PD-1 immune checkpoint inhibitors. The company is working to explore additional tumor types and therapeutic combinations with the candidate through strategic collaboration deals.Importantly, NBTX is evaluating the candidate in a registrational phase III NANORAY-312 study to treat patients with locally advanced head and neck squamous cell cancers. JNJ-1900 enjoys the FDA’s Fast Track designation for the same indication in the United States.Last month, the company announced the completion of the dose escalation and dose expansion parts of an early-stage study evaluating JNJ-1900 in patients with locally advanced pancreatic cancer or borderline resectable pancreatic cancer. Per the data readout from the phase I study, a median overall survival of 23 months from the date of diagnosis was observed in 22 patients treated with the candidate compared to 19.2 months according to historical data. Additionally, JNJ-1900 was generally safe and overall well tolerated.Based on the encouraging results, Nanobiotix has launched a new and additional study cohort, following FDA clearance, evaluating JNJ-1900 in combination with standard-of-care concurrent chemoradiation for pancreatic cancer indications. Enrollment in this cohort is currently ongoing.Nanobiotix S.A. Sponsored ADR Price and Consensus Nanobiotix S.A. Sponsored ADR price-consensus-chart | Nanobiotix S.A. Sponsored ADR QuoteNBTX’s Zacks Rank & Stocks to ConsiderNanobiotix currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks from the sector are Castle Biosciences CSTL and BioMarin Pharmaceutical BMRN, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.In the past 30 days, Castle Biosciences’ earnings estimates for 2024 have remained constant at 34 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 22.7%.CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.In the past 30 days, estimates for BioMarin Pharmaceutical’s 2024 earnings per share have improved from $3.28 to $3.29. Estimates for 2025 earnings per share have decreased from $4.05 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 12.8%.BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.1% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Castle Biosciences, Inc. (CSTL): Free Stock Analysis Report Nanobiotix S.A. Sponsored ADR (NBTX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks